Niagen Bioscience (NAGE) Free Cash Flow (2011 - 2026)
Niagen Bioscience (NAGE) reported Free Cash Flow of -$1.3 million for Q1 2026, down 115.99% year-over-year from $7.9 million in Q1 2025, and down 317.13% quarter-over-quarter from $578000.0 in Q4 2025.
Niagen Bioscience (NAGE) Free Cash Flow (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 14 years of Free Cash Flow data on file, last reported at -$1.3 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$1.3 million, down 115.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (down 78.99% YoY), and the FY2025 annual result was $13.2 million, up 10.6% from the prior year.
- Free Cash Flow fell to -$1.3 million in Q1 2026 per NAGE's latest filing, from $578000.0 in the prior quarter.
- Over five years, Free Cash Flow peaked at $8.5 million in Q4 2024 and troughed at -$7.2 million in Q1 2022.
- A 5-year average of $908235.3 and a median of $578000.0 in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2025 and 2026: Free Cash Flow surged 2990.94% in 2025, then plunged 115.99% in 2026.
- A 5-year view of Free Cash Flow shows it stood at -$500000.0 in 2022, then soared by 225.6% to $628000.0 in 2023, then jumped by 1255.73% to $8.5 million in 2024, then tumbled by 93.21% to $578000.0 in 2025, then tumbled by 317.13% to -$1.3 million in 2026.
- Business Quant data shows NAGE's Free Cash Flow at -$1.3 million in Q1 2026, $578000.0 in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 63,220.27 |
| 10 | Niagen Bioscience | 280.11 Mn | 213.56 Mn | 19.98 Mn | -1.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.26 Mn |
| Mar 31, 2026 | -1.26 Mn |
| Dec 31, 2025 | 578,000.00 |
| Dec 31, 2025 | 578,000.00 |
| Sep 30, 2025 | 3.70 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 1.08 Mn |
| Mar 31, 2025 | 7.85 Mn |
| Mar 31, 2025 | 7.85 Mn |
| Dec 31, 2024 | 8.51 Mn |
| Dec 31, 2024 | 8.51 Mn |
| Sep 30, 2024 | 3.45 Mn |
| Sep 30, 2024 | 3.45 Mn |
| Jun 30, 2024 | -276,000.00 |
| Jun 30, 2024 | -276,000.00 |
| Mar 31, 2024 | 254,000.00 |
| Mar 31, 2024 | 254,000.00 |
| Dec 31, 2023 | 628,000.00 |
| Dec 31, 2023 | 628,000.00 |